← Back to Screener
Dyadic International, Inc. (DYAI)
Price$0.71
Value ScoreD
Growth ScoreB
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-32.88%
Price vs S&P 500 (4W)-7.28%
VGM Score44.65
Market Capitalization$25.89M
All Metrics
Book Value / Share (Quarterly)$0.03
P/TBV (Annual)25.52x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)1.79%
Cash Flow / Share (Quarterly)$-0.16
Price vs S&P 500 (YTD)-32.56%
Gross Margin (TTM)26.10%
Net Profit Margin (TTM)-191.50%
EPS (TTM)$-0.23
10-Day Avg Trading Volume1.10M
EPS Excl Extra (TTM)$-0.23
Revenue Growth (5Y)14.07%
EPS (Annual)$-0.23
ROI (Annual)-117.67%
Gross Margin (Annual)24.93%
Net Profit Margin (5Y Avg)-303.18%
Cash / Share (Quarterly)$0.15
Revenue Growth QoQ (YoY)182.28%
ROA (Last FY)-74.05%
Revenue Growth TTM (YoY)7.13%
EBITD / Share (TTM)$-0.22
ROE (5Y Avg)-221.45%
Operating Margin (TTM)-186.28%
Cash Flow / Share (Annual)$-0.16
P/B Ratio21.01x
P/B Ratio (Quarterly)27.60x
Net Income / Employee (Annual)$-1,227,400
EV / Revenue (TTM)7.01x
Net Interest Coverage (TTM)-32.67x
ROA (TTM)-77.64%
EV / EBITDA (TTM)92.00x
EPS Incl Extra (Annual)$-0.23
Current Ratio (Annual)2.68x
Quick Ratio (Quarterly)2.36x
3-Month Avg Trading Volume0.19M
52-Week Price Return-26.74%
Revenue / Employee (TTM)$634,600
Tangible BV / Share (Quarterly)$0.02
P/S Ratio (Annual)8.38x
Asset Turnover (Annual)0.31x
52-Week High$1.35
Operating Margin (5Y Avg)-321.89%
EPS Excl Extra (Annual)$-0.23
Tangible BV CAGR (5Y)-31.65%
26-Week Price Return-24.96%
Quick Ratio (Annual)2.62x
13-Week Price Return-6.51%
Total Debt / Equity (Annual)4.08x
Current Ratio (Quarterly)2.42x
Enterprise Value$26.68M
Revenue / Share Growth (5Y)10.23%
Asset Turnover (TTM)0.41x
Book Value / Share Growth (5Y)-49.46%
Revenue / Employee (Annual)$515,100
Inventory Turnover (Annual)3.49x
Pretax Margin (Annual)-238.31%
Cash / Share (Annual)$0.20
3-Month Return Std Dev86.25%
Gross Margin (5Y Avg)33.88%
Net Income / Employee (TTM)$-1,215,300
ROE (Last FY)-597.58%
Net Interest Coverage (Annual)-30.85x
EPS Basic Excl Extra (Annual)$-0.23
P/FCF (TTM)17.86x
Receivables Turnover (TTM)6.25x
Total Debt / Equity (Quarterly)4.08x
EPS Incl Extra (TTM)$-0.23
Receivables Turnover (Annual)4.66x
ROI (TTM)-84.44%
P/S Ratio (TTM)6.80x
Pretax Margin (5Y Avg)-303.18%
Revenue / Share (Annual)$0.09
Tangible BV / Share (Annual)$0.06
Price vs S&P 500 (52W)-51.11%
Year-to-Date Return-24.40%
5-Day Price Return-8.43%
EPS Normalized (Annual)$-0.23
ROA (5Y Avg)-69.53%
Net Profit Margin (Annual)-238.31%
Month-to-Date Return-12.05%
EBITD / Share (Annual)$-0.22
Operating Margin (Annual)-232.75%
LT Debt / Equity (Annual)4.08x
ROI (5Y Avg)-94.03%
LT Debt / Equity (Quarterly)4.08x
EPS Basic Excl Extra (TTM)$-0.23
P/TBV (Quarterly)84.50x
P/B Ratio (Annual)27.60x
Inventory Turnover (TTM)0.51x
Pretax Margin (TTM)-191.50%
Book Value / Share (Annual)$0.03
Price vs S&P 500 (13W)-14.77%
Beta1.21x
P/FCF (Annual)5.52x
Revenue / Share (TTM)$0.10
ROE (TTM)-350.86%
52-Week Low$0.65
vGradeD
gGradeB
mGradeD
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.05est. -0.04
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.14
4.14
4.14
4.14
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DYAIDyadic International, Inc. | D | B | D | $0.71 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Dyadic International is a biotechnology company that develops and licenses a gene expression platform based on the C1 fungus (Thermothelomyces heterothallica) for producing industrial enzymes and proteins. The company generates recurring revenue through technology licensing agreements with major industrial partners including BASF, Abengoa Bioenergy, and Codexis for non-pharmaceutical applications.